Yezan Munther Haddadin
Known title: DirectorCIK: 0001718004
Yezan Munther Haddadin's purchase track record
How the stock did after each of Yezan Munther Haddadin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 4 since December 2, 2021
Stock higher 6 months later
0%
3 months: 50%
Median 6-month return
-24.6%
3 months: +5.7%
Beat the S&P 500
0%
median -27.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/26/2026 | OTLK | $39K | +60.0% | pending | — |
| 3/28/2024 | OTLK | $22K | -37.1% | -52.4% | +9.3% |
| 10/6/2022 | OTLK | $43K | -18.3% | -18.3% | +9.6% |
| 12/2/2021 | OTLK | $14K | +29.7% | -24.6% | -8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OTLK | ▲ Buy | Open Market | 29,000 | $24K | 6/2/2026 | View on chart |
| OTLK | ▲ Buy | Open Market | 34,000 | $15K | 5/26/2026 | View on chart |
| OTLK | ▲ Buy | Open Market | 1,882 | $22K | 3/28/2024 | View on chart |
| OTLK | ▲ Buy | Open Market | 3,600 | $5K | 10/7/2022 | View on chart |
| OTLK | ▲ Buy | Open Market | 29,743 | $38K | 10/6/2022 | View on chart |
| OTLK | ▲ Buy | Open Market | 10,000 | $14K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kodiak Sciences stock rises on trial success
Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.
Kodiak Sciences stock rises on trial success. Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.